A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis.

被引：0
|
作者：
Chu, Quincy S.
Sangha, Randeep S.
Hotte, Sebastien J.
Sergenson, Gwen
Chand, Vikram K.
Sufan, Roxana
Gu, Yu
Schnell, David
Hirte, Hal W.
机构：
[1] Cross Canc Ctr, Edmonton, AB, Canada
[2] Juravinski Canc Ctr, Hamilton, ON, Canada
[3] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA
[4] Boehringer Ingelheim Canada Ltd, Burlington, ON, Canada
[5] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2523
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors.
    Adjei, A. A.
    Sosman, J. A.
    Dy, G. K.
    Ma, W.
    Fetterly, G. J.
    Skupien, D.
    Means, J. A.
    Savage, R.
    Chai, F.
    Puzanov, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors
    Raez, Luis E.
    Papadopoulos, Kyriakos
    Ricart, Alejandro D.
    Chiorean, E. Gabriella
    DiPaola, Robert S.
    Stein, Mark N.
    Lima, Caio M. Rocha
    Schlesselman, James J.
    Tolba, Khaled
    Langmuir, Virginia K.
    Kroll, Stewart
    Jung, Donald T.
    Kurtoglu, Metin
    Rosenblatt, Joseph
    Lampidis, Theodore J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 523 - 530
  • [23] A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors
    Luis E. Raez
    Kyriakos Papadopoulos
    Alejandro D. Ricart
    E. Gabriella Chiorean
    Robert S. DiPaola
    Mark N. Stein
    Caio M. Rocha Lima
    James J. Schlesselman
    Khaled Tolba
    Virginia K. Langmuir
    Stewart Kroll
    Donald T. Jung
    Metin Kurtoglu
    Joseph Rosenblatt
    Theodore J. Lampidis
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 523 - 530
  • [24] Phase I/Ib dose-escalation study of aveluma in Chinese patients with advanced solid tumors
    Wu, Yi-Long
    Cheng, Ying
    Chen, Huajun
    Tu, Haiyan
    Xu, Chongrui
    Wang, Zhen
    Liu, Ying
    Xin, Ying
    Lou, Haizhou
    Wang, Wei
    Chin, Kevin
    Li, Dandan
    Zhao, Di
    Gao, Yanfei
    Xu, Wenping
    Pan, Hongming
    FUTURE ONCOLOGY, 2022,
  • [25] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Padda, Sukhmani K.
    Krupitskaya, Yelena
    Chhatwani, Laveena
    Fisher, George A.
    Colevas, Alexander D.
    Pedro-Salcedo, Melanie San
    Decker, Rodney
    Latz, Jane E.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1013 - 1020
  • [26] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Robert, Francisco
    Sandler, Alan
    Schiller, Joan H.
    Liu, Glenn
    Harper, Karen
    Verkh, Lev
    Huang, Xin
    Ilagan, Jennifer
    Tye, Lesley
    Chao, Richard
    Traynor, Anne M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (04) : 669 - 680
  • [27] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Francisco Robert
    Alan Sandler
    Joan H. Schiller
    Glenn Liu
    Karen Harper
    Lev Verkh
    Xin Huang
    Jennifer Ilagan
    Lesley Tye
    Richard Chao
    Anne M. Traynor
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 669 - 680
  • [28] A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
    Harding, James J.
    Telli, Melinda
    Munster, Pamela
    Voss, Martin H.
    Infante, Jeffrey R.
    DeMichele, Angela
    Dunphy, Mark
    Le, Mai H.
    Molineaux, Chris
    Orford, Keith
    Parlati, Frank
    Whiting, Sam H.
    Bennett, Mark K.
    Tannir, Nizar M.
    Meric-Bernstam, Funda
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4994 - 5003
  • [29] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Sukhmani K. Padda
    Yelena Krupitskaya
    Laveena Chhatwani
    George A. Fisher
    Alexander D. Colevas
    Melanie San Pedro-Salcedo
    Rodney Decker
    Jane E. Latz
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1013 - 1020
  • [30] Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors
    Wu, Yi-Long
    Cheng, Ying
    Chen, Huajun
    Tu, Haiyan
    Xu, Chongrui
    Wang, Zhen
    Liu, Ying
    Xin, Ying
    Lou, Haizhou
    Wang, Wei
    Chin, Kevin
    Li, Dandan
    Zhao, Di
    Gao, Yanfei
    Xu, Wenping
    Pan, Hongming
    FUTURE ONCOLOGY, 2022, 18 (17) : 2053 - 2062
12345